ClinConnect ClinConnect Logo
Search / Trial NCT06995846

Application of Bacterial DNA Quantitative Detection in Diagnosis of SBP in Cirrhosis: A Multi Center Diagnostic Experiment

Launched by BEIJING YOUAN HOSPITAL · May 28, 2025

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years, no restriction on gender.
  • Diagnosis of liver cirrhosis based on imaging, biochemical, or hematological evidence of impaired hepatic synthetic function or portal hypertension, or histologically confirmed cirrhosis, regardless of etiology.
  • Diagnosis of ascites according to the 2023 Chinese Clinical Guidelines for the Diagnosis and Treatment of Cirrhotic Ascites and Related Complications.
  • Exclusion Criteria:
  • Patients with confirmed infections in other tissues or organs.
  • Ascites caused by non-hepatic etiologies, such as renal or cardiac ascites.
  • Pregnant individuals, intravenous drug users, or HIV-infected individuals.
  • Patients with uncontrolled hepatocellular carcinoma or other systemic malignancies.
  • Patients who have previously undergone organ transplantation.
  • Patients currently receiving glucocorticoids or other immunosuppressive therapies.

About Beijing Youan Hospital

Beijing Youan Hospital, affiliated with Capital Medical University, is a leading healthcare institution in China renowned for its expertise in infectious diseases and clinical research. With a commitment to advancing medical science and improving patient care, the hospital integrates cutting-edge research methodologies with state-of-the-art clinical facilities. As a prominent clinical trial sponsor, Beijing Youan Hospital actively participates in the development of innovative therapies and treatments, fostering collaboration with international research networks and contributing to the global medical community. Its dedicated team of researchers and clinicians ensures rigorous adherence to ethical standards and regulatory compliance, promoting the safety and well-being of participants throughout the research process.

Locations

Beijing, , China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported